Abbisko Cayman Limited (HK:2256)
:2256
Want to see HK:2256 full AI Analyst Report?
Top Page
Abbisko Cayman Limited
(2256)
Select Model
Select Model
Rating:55Neutral
Price Target:
HK$10.50
▼(-19.35% Downside)
Action:Reiterated
Date:05/02/26
The score is driven primarily by improving financial performance supported by a low-leverage balance sheet and a return to positive profitability and cash generation in 2025, but tempered by uneven cash flow history and recent revenue softness. Technical signals are mixed with the stock below key longer-term averages, and valuation is a major headwind due to the very high P/E and lack of dividend support.
Positive Factors
Improved cash generation
Operating and free cash flow turning positive in 2025 shows the core business began to generate internal funding, reducing reliance on external financing for near-term R&D and development milestones. This improves financial resilience and gives management flexibility to prioritize clinical programs or partnerships.
Negative Factors
Uneven cash flow history
Although 2025 produced positive cash flow, the sharp YoY FCF decline and several prior years of negative cash flow point to inconsistent cash generation. That uneven record raises risk the company may need external funding again if revenue or margin trends reverse, complicating long-term planning.
Read all positive and negative factors
Positive Factors
Negative Factors
Improved cash generation
Operating and free cash flow turning positive in 2025 shows the core business began to generate internal funding, reducing reliance on external financing for near-term R&D and development milestones. This improves financial resilience and gives management flexibility to prioritize clinical programs or partnerships.
Read all positive factors
Abbisko Cayman Limited (2256) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$7.24B
Dividend YieldN/A
Average Volume (3M)4.32M
Price to Earnings (P/E)―
Beta (1Y)1.29
Revenue Growth20.39%
EPS Growth104.43%
CountryHK
Employees281
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.24
Shares Outstanding724,205,300
10 Day Avg. Volume4,319,715
30 Day Avg. Volume4,318,146
Financial Highlights & Ratios
PEG Ratio1.18
Price to Book (P/B)3.79
Price to Sales (P/S)12.24
P/FCF Ratio98.97
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$22.21Price Target Upside70.61% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.47
Revenue Forecast (FY)HK$298.46M
Abbisko Cayman Limited Business Overview & Revenue Model
Company Description
Abbisko Cayman Limited, a clinical-stage biopharmaceutical company, discovers and develops small molecule oncology therapies in the People's Republic of China. Its product candidates are primarily small molecules that focus on small molecule preci...
How the Company Makes Money
null...
Abbisko Cayman Limited Financial Statement Overview
Summary
Income Statement
58
Neutral
Balance Sheet
73
Positive
Cash Flow
52
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 618.84M | 596.28M | 503.99M | 19.06M | 0.00 | 22.68M |
| Gross Profit | 618.84M | 596.28M | 503.99M | 19.06M | 0.00 | 22.68M |
| EBITDA | 96.28M | 48.93M | -15.28M | -410.99M | -492.62M | -1.80B |
| Net Income | 149.98M | 53.82M | 28.30M | -431.58M | -498.29M | -1.81B |
Balance Sheet | ||||||
| Total Assets | 2.44B | 2.35B | 2.11B | 2.12B | 2.49B | 2.65B |
| Cash, Cash Equivalents and Short-Term Investments | 2.38B | 2.10B | 2.01B | 1.96B | 2.35B | 2.57B |
| Total Debt | 17.77M | 303.61M | 24.29M | 35.72M | 45.58M | 53.80M |
| Total Liabilities | 217.96M | 430.41M | 148.71M | 134.28M | 143.16M | 118.48M |
| Stockholders Equity | 2.22B | 1.92B | 1.96B | 1.98B | 2.35B | 2.54B |
Cash Flow | ||||||
| Free Cash Flow | 126.03M | 73.75M | -20.32M | -456.98M | -366.64M | -182.08M |
| Operating Cash Flow | 129.00M | 79.29M | -12.92M | -444.73M | -343.90M | -169.74M |
| Investing Cash Flow | 239.41M | 211.94M | -196.50M | 378.52M | -216.57M | -1.46B |
| Financing Cash Flow | 23.09M | 186.89M | -80.86M | -16.11M | -20.81M | 2.10B |
Abbisko Cayman Limited Technical Analysis
Negative
13.02
Price Trends
12.45
Negative
12.85
Negative
14.06
Negative
Market Momentum
-0.72
Positive
24.25
Positive
8.16
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2256, the sentiment is Negative. The current price of 13.02 is above the 20-day moving average (MA) of 12.15, above the 50-day MA of 12.45, and below the 200-day MA of 14.06, indicating a bearish trend. The MACD of -0.72 indicates Positive momentum. The RSI at 24.25 is Positive, neither overbought nor oversold. The STOCH value of 8.16 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2256.
Abbisko Cayman Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | HK$10.47B | 13.52 | 17.09% | ― | 314.00% | 3032.07% | |
55 Neutral | HK$7.24B | ― | 11.49% | ― | 20.39% | 104.43% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | HK$8.33B | -15.87 | -6.26% | ― | -11.65% | -169.40% | |
50 Neutral | HK$12.15B | -15.04 | -64.19% | ― | -33.37% | -344.90% | |
47 Neutral | HK$15.76B | -27.65 | -18.69% | ― | 57.92% | -23.76% |
* Healthcare Sector Average
HK:2256
Abbisko Cayman Limited
10.00
1.19
13.51%
HK:9966
Alphamab Oncology
8.55
-0.43
-4.79%
HK:1672
Ascletis Pharma, Inc.
14.85
7.85
112.14%
HK:2142
HBM Holdings Ltd.
11.79
2.09
21.55%
HK:2616
CStone Pharmaceuticals
7.70
4.04
110.38%
HK:6955
Shandong Boan Biotechnology Company., Limited. Class H
6.32
-4.68
-42.55%
Abbisko Cayman Limited Corporate Events
Abbisko Cayman Raises HK$517 Million Through Share Placing to Fund Drug Development
Apr 28, 2026
Abbisko Cayman Limited has completed a placing of 42,900,000 new shares under its general mandate at HK$12.18 per share, with all shares subscribed by at least six independent investors who will not become substantial shareholders. The enlarged sh...
Abbisko Moves to Modernise Governance With Digital-Ready Articles Update
Apr 28, 2026
Abbisko Cayman Limited plans to amend its existing Memorandum and Articles of Association and adopt an eleventh amended and restated version to align with updated Hong Kong listing requirements on paperless listings and electronic dissemination of...
Abbisko Cayman Sets 2026 AGM to Approve Results, Board Changes and 20% Share Issue Mandate
Apr 28, 2026
Abbisko Cayman Limited has convened its annual general meeting for May 20, 2026 in Shanghai, where shareholders will review and approve the audited consolidated financial statements for the year ended December 31, 2025, along with the reports of t...
Abbisko Showcases Broad Oncology Pipeline with Pan‑KRAS Data at 2026 AACR
Apr 23, 2026
Abbisko Therapeutics, a subsidiary of Abbisko Cayman Limited, reported that it presented six preclinical and translational oncology research programs at the 2026 American Association for Cancer Research Annual Meeting in San Diego. The portfolio o...
Abbisko Cayman to Raise HK$517 Million via Discounted Share Placing for R&D Push
Apr 21, 2026
Abbisko Cayman Limited has launched a share placing under its general mandate, agreeing with a sole placing agent to place 42.9 million new shares to at least six institutional investors at HK$12.18 per share, an 8–9% discount to recent mark...
Abbisko Grants 290,000 Share Options to Employees Under Post-IPO Scheme
Apr 8, 2026
Abbisko Cayman Limited has granted 290,000 share options to three employees under its Post-IPO Share Option Scheme, with an exercise price of HK$13.14, vesting in four equal tranches on each anniversary from April 8, 2027 to April 8, 2030, subject...
Abbisko Wins EMA Orphan Drug Status for Liver Cancer Therapy Irpagratinib
Mar 31, 2026
Abbisko Therapeutics, a subsidiary of Abbisko Cayman Limited, has developed irpagratinib, a highly selective oral FGFR4 inhibitor targeting FGF19‑overexpressing hepatocellular carcinoma, a segment of primary liver cancer with limited effecti...
Abbisko Wins FDA IND Clearance for Pediatric Achondroplasia Drug ABSK061
Mar 30, 2026
Abbisko Therapeutics, a subsidiary of Abbisko Cayman Limited, has received U.S. FDA clearance for an Investigational New Drug application for ABSK061, a highly selective FGFR2/3 inhibitor, to treat children with achondroplasia. The candidate has a...
Abbisko Wins FDA Orphan Drug Status for Achondroplasia Candidate ABSK061
Mar 19, 2026
Abbisko Therapeutics, a subsidiary of Abbisko Cayman Limited, has received Orphan Drug Designation from the U.S. Food and Drug Administration for its orally administered, highly selective FGFR2/3 inhibitor ABSK061 to treat achondroplasia. The cand...
Abbisko Starts Phase II Trial of Irpagratinib Combo for Advanced Liver Cancer
Mar 16, 2026
Abbisko Therapeutics has begun dosing the first patient in a Phase II trial of its FGFR4 inhibitor irpagratinib in combination with toripalimab and a bevacizumab biosimilar as a first-line treatment for advanced or unresectable hepatocellular carc...
Abbisko Wins FDA Rare Pediatric Disease Status for Achondroplasia Drug ABSK061
Mar 11, 2026
Abbisko Cayman Limited said its subsidiary Abbisko Therapeutics has secured U.S. FDA Rare Pediatric Disease designation for ABSK061, an oral, highly selective FGFR2/3 inhibitor being developed to treat achondroplasia in children. The candidate, cu...
Abbisko’s TGCT Drug Pimicotinib Clears Key Global Milestone With Lancet Phase 3 Publication
Mar 9, 2026
Abbisko Cayman’s subsidiary Abbisko Therapeutics has reported that results from its global Phase 3 MANEUVER trial of pimicotinib in tenosynovial giant cell tumour have been published in The Lancet, underscoring the quality and robustness of ...
Abbisko Advances KRAS G12D Cancer Program With First Patient Dosed in ABSK141 Trial
Mar 4, 2026
Abbisko Therapeutics, the oncology-focused subsidiary of Abbisko Cayman Limited, has advanced its pipeline with the first patient dosing in a Phase I/II trial of ABSK141, an oral, highly potent and selective small-molecule inhibitor targeting KRAS...
Abbisko Chairman Boosts Stake, Signalling Confidence While Maintaining Public Float
Mar 3, 2026
Abbisko Cayman Limited announced that its founder, executive director, chief executive officer and chairman, Dr. Xu Yao-Chang, has increased his stake in the company by purchasing 45,000 shares on the open market on March 3, 2026, at an average pr...
Abbisko Wins First China Drug Approval, Reshuffles Secretaries as Merck Deepens Tie-Up
Mar 2, 2026
Abbisko reported its annual results for 2025 alongside corporate governance changes, including the resignation of Dr. Yu Hongping and Ms. Chan Yin Wah as joint company secretaries and the appointment of Ms. Zhang Hanxi and Ms. Lin Sio Ngo as their...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.